New painkiller could cut opioid use after knee surgery
NCT ID NCT07430085
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a long-acting painkiller (bupivacaine-meloxicam) can reduce pain and the need for opioid medications after robot-assisted knee replacement. 150 adults with knee osteoarthritis will receive either the new painkiller or a standard injection. Researchers will measure pain levels and opioid use for 72 hours after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bupivacaine-meloxicam extended-release solution
What this could lead to
If it works, this could offer a better way to manage pain after knee replacement, reducing the need for opioids.
What could go wrong
This is a small, early-phase study (Phase 4) with only 150 participants. The results may not apply to everyone, and there is a risk of side effects like allergic reactions or kidney problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS (OA) OF THE KNEE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••